2026 American Society of Clinical Oncology (ASCO)
ASCO 2026 Prostate Cancer
- ASCO 2026: Discussant - Moving Beyond Beta-Emitters: The Next Generation Radioligand Therapies in Prostate Cancer
- ASCO 2026: Discussant – Switching Gears: Tuning the Targeting Moiety of PSMA Directed Radioligand Therapy
- ASCO 2026: Radioligand Revolutions: Where We Are Now and Where We Are Going
- ASCO 2026: External Validation of New Prostate Cancer Risk Groups by PSMA-PET (PPP3)
- ASCO 2026: First-Line Metastatic Castration-Resistant Prostate Cancer: One Size Doesn't Fit All
ASCO 2026 Bladder Cancer
- ASCO 2026: Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized MIBC Patients: SASAN-SPARING Trial
- ASCO 2026: TROPION-Urothelial03: A Phase 2/3 Study of Datopotamab Deruxtecan + Platinum Based Chemotherapy versus Gemcitabine + Platinum Based Chemotherapy
- ASCO 2026: Avelumab + Sacituzumab Govitecan versus Avelumab Monotherapy as First Line Maintenance Treatment for Advanced Urothelial Carcinoma: Updated Subgroup Analyses of JAVELIN Bladder Medley Based on Metastatic Sites
- ASCO 2026: Bulumtatug Fuvedotin + Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Follow-up Results from a Phase 1b/2 Study
- ASCO 2026: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab Versus Avelumab After First Line Platinum Based Chemotherapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (Alliance A032001)
ASCO 2026 Kidney Cancer
- ASCO 2026: Cabozantinib + Nivolumab versus Sunitinib in Patients with Advanced RCC and Bone Metastasis: Updated Subgroup Analysis of the Phase 3 CheckMate-9ER Trial
- ASCO 2026: Cabozantinib + Nivolumab versus Sunitinib in Patients with Advanced RCC and Liver Metastasis: Subgroup Analysis of the Phase 3 CheckMate-9ER Trial
- ASCO 2026: AI-Augmented Analysis of Quantitative ctDNA Burden and Longitudinal Kinetics to Identify Prognostic Risk Stratification in Metastatic Clear Cell RCC
- ASCO 2026: Final Results of a Phase 2 Trial of Cabozantinib + Nivolumab in Patients with Non Clear Cell RCC
- ASCO 2026: Prospective Clinical Activity and Preclinical Basis of Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: A Collaborative Multi-Institutional Study